title: Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
abstract: OBJECTIVE
  The antitumor effect of CPT-11, a camptothecin derivative, on two human testicular embryonal carcinomas (TTSC-2 and TTSC-3) heterotransplanted into-nude mice was studied.
  
  
  METHODS
  Tumor-bearing nude mice were given daily intraperitoneal injections of the anticancer drugs in 0.1 ml saline 3 times at 3-day intervals. At the end of the experiments tumors were resected and subjected to light-microscopic observation.
  
  
  RESULTS
  When 10, 30 and 50 mg/kg of CPT-11 was administered to tumor-bearing mice intraperitoneally, the antitumor effect of CPT-11 was observed dose-dependently in both TTSC-2 and TTSC-3. When 30 mg/kg of CPT-11 was administered in combination with CDDP, complete tumor regression was observed in both TTSC-2 and TTSC-3 tumors. Histological findings correlated well with the decrease in tumor volume of treated tumors. No mice died after treatment with CPT-11 in a single-agent and combination chemotherapy.
  
  
  CONCLUSIONS
  Chemotherapy with CPT-11 was an effective and safe method against human testicular tumors heterotransplanted in nude mice.
authors.affiliation: Department of Urology, Osaka University Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Miki
authors.forename: M
authors.initials: M
authors.lastname: Sawada
authors.forename: N
authors.initials: N
authors.lastname: Nonomura
authors.forename: Y
authors.initials: Y
authors.lastname: Kojima
authors.forename: A
authors.initials: A
authors.lastname: Okuyama
authors.forename: O
authors.initials: O
authors.lastname: Maeda
authors.forename: S
authors.initials: S
authors.lastname: Saiki
authors.forename: T
authors.initials: T
authors.lastname: Kotake
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D018243:Teratocarcinoma / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors; D014183:Transplantation, Heterologous; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D059004:Topoisomerase I Inhibitors; C058816:DWA 2114; D014747:Vinblastine; D005047:Etoposide; D000077146:Irinotecan; C053989:nedaplatin; D016190:Carboplatin; D002945:Cisplatin; D002166:Camptothecin